GlassScriptPhysician profile
Patty L Cheng
NPI 1265526263
$13,155.10
in general payments reported to CMS, 2019-2025
24 companies · $3,787 in 2025
The $3,787 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,472 · 2020: $336 · 2021: $728 · 2022: $1,784 · 2023: $1,818 · 2024: $3,230 · 2025: $3,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,325 · Travel and Lodging: $2,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,324.53 |
| Travel and Lodging | $2,510.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,526.19 | 2019-2025 | Tryptyr, Wavelight Ex500 Excimer Laser, Clareon |
| Bausch & Lomb Americas INC. | $1,748.96 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Amgen INC. | $804.28 | 2024-2025 | Tepezza |
| Glaukos Corporation | $641.00 | 2024-2025 | Idosetr, Kxl System (Not Refurbished), Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $585.96 | 2020-2021 | |
| Ocular Therapeutix, INC. | $499.30 | 2022-2024 | Dextenza |
| Sun Pharmaceutical Industries INC. | $462.68 | 2021-2023 | Cequa |
| Tarsus Pharmaceuticals, INC. | $370.29 | 2024-2025 | Xdemvy |
| Allergan, INC. | $348.60 | 2021-2022 | |
| Horizon Therapeutics Plc | $328.89 | 2022-2023 | Tepezza |
| Sight Sciences, INC. | $293.16 | 2021-2025 | Omni Surgical System |
| Abbvie INC. | $267.42 | 2023 | Vuity, Lumigan |
| Apellis Pharmaceuticals, INC. | $235.17 | 2023 | Syfovre |
| Novartis Pharmaceuticals Corporation | $182.63 | 2019-2022 | |
| Biotissue Holdings INC. | $162.51 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $126.66 | 2024 | Vevye |
| Oyster Point Pharma, INC. | $126.24 | 2022 | |
| Shire North American Group INC | $120.43 | 2019 | |
| Coopervision INC. | $100.00 | 2019 | |
| Eyevance Pharmaceuticals LLC | $80.78 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.46 | 2022 | |
| Kala Pharmaceuticals, INC. | $47.58 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $24.77 | 2025 | |
| Rxsight INC | $16.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patty Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.